Shinn, E., Zahrieh, D., DeMichele, A., Zdenkowski, N., Lemieux, J., Mao, J., Bjelic-Radisic, V., Naughton, M. J., Pfeiler, G., Gelmon, K., Balko, J. M., Egle, D., Zoppoli, G., Traina, T., Jimenez, M. M., Novoa, S. A., Haddad, T., Chan, A., Ring, A., Wolff, A., Symanns, W. F., Lorenzo, J. P., Sabanatha, D., Burstein. H. J., Bellet-Ezquerra, M., Foukakis, T., Novik, Y., Rubovszky, G., Singer, C. F., Muehlbacher, K., Filho, O. M., Goulioti, T., Law, E., Partridge, A. H., Carey, L. A., Zoroufy, A., Hlauschek, D., Fesl, C., Mayer, E. L., Gnant, M. Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer , Breast Cancer Res Treat: 2025

Hahnen, E., Hauke, J., Gelmon, K., Marmé, F., Ernst, C., Martin, M., Untch, M., Bonnefoi, H., Knudsen, E., Im, S.-A., DeMichele, A., Van’t Veer, L., Kim, S.-B., Bear, H., McCarthy, N., Rhiem, K., Turner, N., Witkiewicz, A., Rojo, F., Filipits, M., Martin, LA., Fasching, P. A., Schem, C., Becker, K., García-Sáenz, J. A., Kelly, C. M., Reimer, T., Toi, M., Rugo, H. S., Denkert, C., Gnant, M., Makris, A., Liu, Y., Valota, O., Felder, B., Weber, K., Nekljudova, V., Loibl, S. BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis , JCO Precision Oncology: 2025

Thomas, A., Mayer, E. L., DeMichele, A., Harbeck, N., Curigliano, G., Ignatiadis, M., Adam, V., Zhou, Y., Brown, T. P., Gilham, L., Chua, B. H., Kalinsky, K., Wolff, A. C., & O'Reilly, S. Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive Breast Cancer , J Clin Oncol: 2025

Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, Untch M, Bonnefoi H, Kim S, Seiler S, Bear HD, Witkiewicz AK, Im S, DeMichele A, Pehl A, Van't Veer L, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff CC, Kelly CM, Reimer T, Felder B, Olivé MM, Knudsen ES, Turner N, Rojo F, Schmitt WD, Fasching PA, Teply-Szymanski J, Zhang Z, Toi M, Rugo HS, Gnant M, Makris A, Holtschmidt J, Nekljudova V, Loibl S Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping , Cancer Cell: 2025

Huppert, L. A., Wolf, D., Yau, C., Brown-Swigart, L., Hirst, G. L., Isaacs, C., Pusztai, L., Pohlmann, P. R., DeMichele, A., Shatsky, R., Yee, D., Thomas, A., Nanda, R., Perlmutter, J., Heditsian, D., Hylton, N., Symmans, F., Van't Veer, L. J., Esserman, L., & Rugo, H. S. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial , Annals of Oncology: 2025

Li, W., Onishi, N., Gibbs, J. E., Wilmes, L. J., Le, N. N., Metanat, P., Price, E. R., Joe, B. N., Kornak, J., Yau, C., Wolf, D. M., Magbanua, M. J. M., LeStage, B., van 't Veer, L. J., DeMichele, A. M., Esserman, L. J., & Hylton, N. M. MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer , Tomography: 2025

Mukhtar, R. A., Gottipati, S., Yau, C., López-Tarruella, S., Earl, H., Hayward, L., Hiller, L., Osdoit, M., van der Noordaa, M., de Croze, D., Hamy, A. S., Laé, M., Reyal, F., Sonke, G. S., Steenbruggen, T. G., van Seijen, M., Wesseling, J., Martín, M., Del Monte-Millán, M., Boughey, J. C., Goetz, M. P., Hoskin, T., Valero, V. Edge, S. B., Abraham, J. E., Bartlett, J. M. S., Caldas, C., Dunn, J., Provenzano, E., Sammut, S. J., Thomas, J. S., Graham, A., Hall, P., Mackintosh, L., Fan, F., Godwin, A. K., Schwensen, K., Sharma, P., DeMichele, A. M., Cole, K., Pusztai, L., Kim, M., van 't Veer, L. J., Cameron, D., Laura J Esserman, L. J., Fraser Symmans, W. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer , NPJ Breast Cancer: 2025

O'Hara, M. H., Jegede, O., Dickson, M. A., DeMichele, A. M., Piekarz, R., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L. V., Patton, D. R., Williams, P. M., Hamilton, S. R., Onitilo, A., Tricoli, J. V., Conley, B. A., Arteaga, C. L., Harris, L. N., O'Dwyer, P. J., Chen, A. P., & Flaherty, K. T. Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C , Clin Cancer Res: 2025

Rugo, H. S., Campbell, M., Yau, C., Jo Chien, A., Wallace, A. M., Isaacs, C., Boughey, J. C., Han, H. S., Buxton, M., Clennell, J. L., Asare, S. M., Steeg, K., Wilson, A., Singhrao, R., Matthews, J. B., Perlmutter, J., Fraser Symmans, W., Hylton, N. M., DeMichele, A. M., Yee, D., Van't Veer, L. J., Berry, D. A., Esserman, L. J. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer , Breast Cancer Res Treat : 2024

Young, A. J., Pantel, A. R., Kiani, M., Doot, R. K., Bagheri, S., Pryma, D. A., Farwell, M. D., Li, S., Lee, H., Schubert, E. K., Secreto, A., Zuckerman, S. P., Nayak, A., Choi, H., Carlin, S., DeMichele, A., Mankoff, D. A., Zhou, R., Mach, R. H., & McDonald, E. S. Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET in Breast Cancer , J Nucl Med: 2024